India Plots a Fresh Push to Strengthen Bulk‑Drug R&D Capacity

New Delhi – In a move that could reshape the country’s pharmaceutical landscape, the pharma secretary told reporters on Wednesday that the Ministry is quietly stitching together a scheme designed to beef up research and development capacity for bulk‑drug manufacturing. The plan, still in the drafting stage, is expected to roll out later this year.

India currently relies heavily on imported active pharmaceutical ingredients (APIs). While the nation enjoys a strong generic‑drug market, the lack of robust R&D facilities for bulk chemicals has long been a thorn in the side of self‑sufficiency advocates. "We want to change that narrative," the secretary said, adding that the scheme will target both existing manufacturers looking to upgrade and new players eager to enter the space.

What does the proposed programme entail? While exact figures are being fine‑tuned, sources say it will blend capital grants, low‑interest loans and tax holidays to lower the barrier for setting up state‑of‑the‑art R&D labs and pilot plants. In addition, the government plans to create a single‑window clearance system to speed up approvals – a welcome breath of fresh air for an industry often tangled in red tape.

Industry bodies have welcomed the news, calling it a timely push that aligns with the broader "Make in India" agenda. "We’ve been urging the government for a focused push on API R&D for years," said a senior executive of the Indian Pharmaceutical Association. "If this scheme delivers on its promises, it could spark a wave of innovation and, crucially, reduce our import bill."

Critics, however, caution that the success of any incentive program hinges on transparent implementation and clear eligibility criteria. They warn that without stringent monitoring, funds could drift into projects with little commercial viability.

Nevertheless, the pharma secretary expressed confidence that the scheme will be rolled out with robust oversight mechanisms. "We are drafting detailed guidelines to ensure the money reaches genuine innovators," he affirmed.

As the world watches India’s push to become a global hub for cost‑effective medicines, this upcoming scheme could be the missing link between production capacity and cutting‑edge research, stitching together a more resilient, home‑grown pharmaceutical ecosystem.